Drug Approval | October 14, 2021
IOL receives Korean FDA approval
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
It has planned an investment of over Rs 80 crore in the next five years
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The company plans to expand its portfolio in regulated markets aggressively
A total of 8308 stores are open across India and medicines are priced at affordable rates
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
Subscribe To Our Newsletter & Stay Updated
